Tags

Type your tag names separated by a space and hit enter

Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
Mov Disord. 2014 May; 29(6):750-5.MD

Abstract

An inverse relationship between Parkinson's disease (PD) and cancer has been described. However, the association between cancers and genetic forms of PD, in particular the R1441G mutation in the LRRK2 gene, is not well known. The objective of this work was to analyze cancer prevalence in PD patients with R1441G or G2019S mutations in LRRK2, and in idiopathic PD (iPD). A total of 732 patients with PD (70 and 25 carriers of R1441G or G2019S mutations, respectively), and 177 controls, were linked using a population-based cancer registry of the Spanish province of Gipuzkoa. Cancer prevalence was not significantly higher in PD-G2019S carriers (20%) than in PD-R1441G carriers (14.3%), iPD (13.8%), or controls (12.5%). With the exception of a high prevalence of hematological cancers (crude odds ratio of 7.1) in the R1441G group, specific cancer types were not increased in PD mutation carriers. In both the carrier and iPD groups, cancers were diagnosed after the onset of PD. PD patients had a similar prevalence of cancer to control subjects. There was no increased association between G2019S or R1441G mutations and any type of cancer. Although there was a higher prevalence of hematological cancers in the R1441G group, the low number of such cancers overall makes this finding of uncertain significance. There was a slightly higher but not statistically significant prevalence of non-skin cancers in the G2019S group, suggesting that further study to evaluate the association should be undertaken prior to ascribing an increased cancer risk to this population.

Authors+Show Affiliations

Department of Neurology, University Hospital Donostia, San Sebastián, Spain; Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain; Neurosciences Area, Biodonostia Institute, San Sebastián, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24357540

Citation

Ruiz-Martínez, Javier, et al. "Prevalence of Cancer in Parkinson's Disease Related to R1441G and G2019S Mutations in LRRK2." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 29, no. 6, 2014, pp. 750-5.
Ruiz-Martínez J, de la Riva P, Rodríguez-Oroz MC, et al. Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2. Mov Disord. 2014;29(6):750-5.
Ruiz-Martínez, J., de la Riva, P., Rodríguez-Oroz, M. C., Mondragón Rezola, E., Bergareche, A., Gorostidi, A., Gago, B., Estanga, A., Larrañaga, N., Sarasqueta, C., López de Munain, A., & Martí Massó, J. F. (2014). Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2. Movement Disorders : Official Journal of the Movement Disorder Society, 29(6), 750-5. https://doi.org/10.1002/mds.25778
Ruiz-Martínez J, et al. Prevalence of Cancer in Parkinson's Disease Related to R1441G and G2019S Mutations in LRRK2. Mov Disord. 2014;29(6):750-5. PubMed PMID: 24357540.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2. AU - Ruiz-Martínez,Javier, AU - de la Riva,Patricia, AU - Rodríguez-Oroz,Maria C, AU - Mondragón Rezola,Elisabet, AU - Bergareche,Alberto, AU - Gorostidi,Ana, AU - Gago,Belen, AU - Estanga,Ainara, AU - Larrañaga,Nerea, AU - Sarasqueta,Cristina, AU - López de Munain,Adolfo, AU - Martí Massó,José F, Y1 - 2013/12/19/ PY - 2013/06/13/received PY - 2013/10/01/revised PY - 2013/10/07/accepted PY - 2013/12/21/entrez PY - 2013/12/21/pubmed PY - 2014/12/20/medline KW - G2019S KW - LRRK2 KW - Parkinson's disease KW - R1441G KW - cancer SP - 750 EP - 5 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 29 IS - 6 N2 - An inverse relationship between Parkinson's disease (PD) and cancer has been described. However, the association between cancers and genetic forms of PD, in particular the R1441G mutation in the LRRK2 gene, is not well known. The objective of this work was to analyze cancer prevalence in PD patients with R1441G or G2019S mutations in LRRK2, and in idiopathic PD (iPD). A total of 732 patients with PD (70 and 25 carriers of R1441G or G2019S mutations, respectively), and 177 controls, were linked using a population-based cancer registry of the Spanish province of Gipuzkoa. Cancer prevalence was not significantly higher in PD-G2019S carriers (20%) than in PD-R1441G carriers (14.3%), iPD (13.8%), or controls (12.5%). With the exception of a high prevalence of hematological cancers (crude odds ratio of 7.1) in the R1441G group, specific cancer types were not increased in PD mutation carriers. In both the carrier and iPD groups, cancers were diagnosed after the onset of PD. PD patients had a similar prevalence of cancer to control subjects. There was no increased association between G2019S or R1441G mutations and any type of cancer. Although there was a higher prevalence of hematological cancers in the R1441G group, the low number of such cancers overall makes this finding of uncertain significance. There was a slightly higher but not statistically significant prevalence of non-skin cancers in the G2019S group, suggesting that further study to evaluate the association should be undertaken prior to ascribing an increased cancer risk to this population. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/24357540/Prevalence_of_cancer_in_Parkinson's_disease_related_to_R1441G_and_G2019S_mutations_in_LRRK2_ L2 - https://doi.org/10.1002/mds.25778 DB - PRIME DP - Unbound Medicine ER -